Pharmaceutical Technology

JUNE 16, 2023

France-based biotech company Osivax has thrown its hat into the influenza ring by dosing the first subject with its vaccine candidate OVX836. The Phase IIa trial (NCT05734040) in Australia will see a potential 500 volunteers given OVX836 in combination with quadrivalent influenza vaccines (QIVs).

Vaccine 246

Vaccine Vaccination Trials Immune Response 246

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccine 245

Vaccine Vaccination Development Allergies 245

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The vaccine also produced a T-cell response within 28 days, a secondary outcome.

Immune Response 107

Immune Response Vaccine Vaccination Trials 107

Pharma Times

DECEMBER 8, 2023

One-third of patients who received Pfizer’s COVID-19 vaccine had unintended immune responses - News - PharmaTimes

Immune Response 159

Immune Response Research Vaccination Vaccine 159

Medical Xpress

APRIL 20, 2023

A new HIV vaccine from Scripps Research has shown a significantly improved ability to neutralize the virus in preclinical tests, and it will soon be studied in healthy people who volunteer to participate in clinical trials.

Immune Response 109

Immune Response Vaccine Vaccination Clinical Trials 109

Medical Xpress

JANUARY 4, 2023

Myocarditis, a condition in which the heart muscle becomes inflamed, is a rare complication that can occur after mRNA COVID vaccination. It's estimated that roughly 18 cases occur in every 1 million vaccine doses administered, making it so rare that it is challenging to find cases to investigate.

Immune Response 96

Immune Response Protein Vaccine Vaccination 96

Pharma Times

JUNE 29, 2021

Mixing different vaccines produces a strong immune response against virus, according to researchers

Immune Response 130

Immune Response Vaccine Vaccination Research 130

Pharma Times

JULY 18, 2021

Studies showed immunosuppression appeared to weaken immune responses to COVID-19 vaccines

Immune Response 123

Immune Response Vaccine Vaccination Research 123

Scienmag

JANUARY 28, 2022

ATLANTA—An influenza vaccine administered through the nose and constructed with nanoparticles that enhance immune response offers strong protection against different influenza virus strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

Immune Response 95

Immune Response Vaccine Vaccination Research 95

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

Vaccine 145

Vaccine Vaccination Trials Immune Response 145

World of DTC Marketing

AUGUST 21, 2020

million people have been infected and over 165,000 have died, the promise of a vaccine is hampered by a vexing epidemic that long preceded Covid-19: obesity. The finding was replicated in a follow-up study that used longer needles to ensure the vaccine was injected into muscle and not fat. In the United States, where at least 4.6

Immune Response 238

Immune Response Vaccine Vaccination Scientist 238

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. Other efforts to develop a nasally-delivered COVID-19 vaccine have met with greater success.

Vaccine 116

Vaccine Vaccination Immune Response Development 116

World of DTC Marketing

AUGUST 3, 2020

QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. Personally I would want to know as much as I can before I ask for the vaccine but I also know that greed can make people do stupid things and there is a lot of money at stake here.

Vaccine 155

Vaccine Vaccination Immune Response Trials 155

World of DTC Marketing

APRIL 11, 2021

QUICK THOUGHT: People believe the COVID-19 vaccine was developed in less than a year but that’s not true. Further scientific research into the virus and recognition that it was not like influenza A, a flu virus known to cause bronchitis, would transpire over the next 30 years. . Funding was not the only issue. Do Lockdowns Work?

Vaccine 303

Vaccine Vaccination Clinical Trials Clinical Trials 303

Velocity Clinical Research

MARCH 19, 2025

Charles Eger, MD, contributed to new research on a combination vaccine intended to provide protection against both seasonal flu and COVID-19 in a single shot. Full article: [link] The post Charles Eger, MD, Authors New Article in Nature Medicine appeared first on Velocity Clinical Research.

Medicine 52

Medicine Immune Response Vaccine Vaccination 52

pharmaphorum

FEBRUARY 25, 2021

Pfizer/BioNTech’s mRNA vaccine against COVID is a technical marvel – but the ultra-cool temperatures required for storage and stability has been tricky to handle. A nasal delivery method will also produce an immune response at the point where the virus enters the body.

Vaccine 111

Vaccine Vaccination Immune Response Trials 111

Medical Xpress

JANUARY 25, 2023

Immunity from COVID-19 appears to gather strength with more time between vaccination and infection, a new laboratory study from researchers at Oregon Health & Science University suggests. The findings carry implications for vaccine recommendations as the pandemic transitions to an endemic state.

Immune Response 75

Immune Response Research Vaccine Vaccination 75

Pharma Times

DECEMBER 20, 2023

The Novo Nordisk Foundation has committed $260m to establish a new state-of-the-art research and vaccine development initiative to help combat deadly airborne infections. The initiative aims to create new or improved vaccines for deadly respiratory diseases, including tuberculosis (TB) and influenza. million deaths every year.

Vaccine 110

Vaccine Vaccination Immune Response Bacteria 110

pharmaphorum

MARCH 15, 2021

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. This is made possible using ‘Advanced Host Immune Response Technologies’. The pace of work in the industry reached almost ludicrous speeds.

Immune Response 71

Immune Response Vaccination Vaccine Development 71

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front.

Vaccine 134

Vaccine Vaccination Clinical Trials Clinical Trials 134

XTalks

NOVEMBER 12, 2024

Moreover, in low- and middle-income countries, lack of healthcare access increases the disease’s impact, as limited diagnostics, vaccination coverage and medical resources limit early detection and treatment. These therapies work by controlling excessive inflammatory responses in the lungs.

Bacteria 110

Bacteria Life Science Vaccine Vaccination 110

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccine 105

Vaccine Vaccination Research Immune Response 105

XTalks

OCTOBER 12, 2021

Last week, a study that “stumbled upon” a vaccine for rheumatoid arthritis (RA) was published in the Proceedings of the National Academy of Sciences. The experimental arthritis vaccine was developed by researchers at the University of Toledo (UToledo) and is a major breakthrough for rheumatoid arthritis and other autoimmune diseases as well.

Vaccine 105

Vaccine Vaccination Research Immune Response 105

Scienmag

MARCH 10, 2022

Close interactions with infectious disease set both University of California, Santa Cruz graduate student Ana Nuñez Castrejon and Associate Professor of Biomolecular Engineering Rebecca DuBois on the path of studying Respiratory syncytial virus (RSV), a common and sometimes dangerous respiratory disease for which there is not currently a vaccine.

Immune Response 77

Immune Response Vaccine Vaccination Protein 77

Scienmag

JUNE 3, 2021

Strong immune responses to unchanging, conserved parts of the 2009 H1N1 pandemic flu virus suggest strategies for effective universal vaccines Credit: Guthmiller et al.

Immune Response 98

Immune Response Vaccine Vaccination Development 98

Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccine 104

Vaccine Vaccination Immune Response Allergies 104

BioPharma Reporter

MARCH 18, 2021

Researchers have highlighted nutrition as a possible factor influencing the effectiveness of the COVID-19 vaccine, as recent news establishes a link between vitamin D levels and an adequate immune response.

Immune Response 98

Immune Response Vaccine Vaccination Research 98

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

Vaccine 130

Vaccine Vaccination Development Immune Response 130

Medical Xpress

MARCH 3, 2023

A preclinical study evaluating a Kiwi-made COVID-19 vaccine—Kiwi Vax—has shown its unique formulation induces a safe and highly effective immune response to SARS-CoV-2 variants of concern, making it a promising booster vaccine candidate.

Vaccine 104

Vaccine Vaccination Immune Response Research 104

pharmaphorum

JANUARY 8, 2021

The Pfizer/BioNTech vaccine appears to work against an important mutation in the new coronavirus variants causing havoc in the UK and South Africa, according to research from the drugs giant. The study team tested blood taken from people who had received the mRNA vaccine developed by BioNTech and Pfizer.

Scientist 124

Scientist Vaccine Vaccination Immune Response 124

BioSpace

OCTOBER 14, 2021

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Immune Response 81

Immune Response Vaccination Vaccine Research 81

Medical Xpress

DECEMBER 5, 2022

Research by RCSI University of Medicine and Health Sciences has provided new insights into the mechanism behind how our circadian 24-hour body clock influences our immune response to vaccines, depending on the time of day.

Vaccine 75

Vaccine Vaccination Immune Response Research 75

The Pharma Data

OCTOBER 26, 2020

AstraZeneca’s COVID-19 vaccine candidate, AZD1222, elicited immune responses in older coronavirus patients similar to ones generated in younger adults, lending more promise to a vaccine that’s seen as one of the leading contenders in the race to become the first approved COVID-19 vaccine. Source link.

Immune Response 52

Immune Response Vaccine Vaccination Research 52

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccine 119

Vaccine Vaccination Bacterium Protein 119

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccine 130

Vaccine Vaccination Containment Immune Response 130

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. Sanofi is one of the leading patent filers for Flavivirus vaccine components.

Vaccine 130

Vaccine Vaccination Protein Immune Response 130

The Pharma Data

OCTOBER 22, 2020

AstraZeneca’s COVID-19 vaccine candidate, AZD1222, currently being evaluated in phase 3 global trials, delivers a strong immune response, according to a new UK study. Source link.

Immune Response 52

Immune Response Vaccine Vaccination Trials 52